Redwood Wealth Management Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$485K Sell
17,262
-1,174
-6% -$31.3K 0.21% 93
2025
Q4
$459K Sell
18,436
-3,496
-16% -$88.2K 0.19% 99
2025
Q3
$559K Sell
21,932
-1,476
-6% -$36.4K 0.24% 88
2025
Q2
$567K Sell
23,408
-1,465
-6% -$34.2K 0.25% 88
2025
Q1
$630K Sell
24,873
-279
-1% -$7.3K 0.32% 70
2024
Q4
$667K Buy
25,152
+79
+0.3% +$2.14K 0.33% 67
2024
Q3
$726K Buy
25,073
+208
+0.8% +$6.07K 0.36% 62
2024
Q2
$696K Buy
24,865
+1,405
+6% +$38.7K 0.52% 39
2024
Q1
$651K Buy
23,460
+2,217
+10% +$61.5K 0.69% 38
2023
Q4
$612K Buy
21,243
+970
+5% +$29.3K 0.68% 40
2023
Q3
$672K Buy
20,273
+11
+0.1% +$389 0.79% 33
2023
Q2
$743K Buy
20,262
+1,313
+7% +$51.1K 0.82% 29
2023
Q1
$773K Buy
18,949
+1,236
+7% +$53.4K 0.88% 29
2022
Q4
$908K Buy
+17,713
New +$849K 1.13% 20

Other funds holding PFE

Redwood Wealth Management Group's PFE Position: Q1 2026 in Review

Redwood Wealth Management Group reduced its Pfizer (PFE) stake by 6.4% in Q1 2026, selling an estimated $31.3K and leaving 17,262 shares worth $485K. The position accounts for 0.21% of the portfolio, ranked #93.

Redwood Wealth Management Group first reported a position in PFE in Q4 2022 and has held it in 14 quarters since. The position peaked at $908K in Q4 2022. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Redwood Wealth Management Group held 17,262 shares of Pfizer worth $485K as of Q1 2026.
  • Redwood Wealth Management Group sold 1,174 Pfizer shares in Q1 2026, an estimated $31.3K.
  • Pfizer made up 0.21% of Redwood Wealth Management Group's portfolio in Q1 2026, its #93 holding.
  • Redwood Wealth Management Group first reported a position in Pfizer in Q4 2022 and has held it in 14 quarters since.
  • Redwood Wealth Management Group's Pfizer position peaked at $908K in Q4 2022.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Redwood Wealth Management Group's 13F filing for Q1 2026, filed 24 Apr 2026.